22 research outputs found

    Treatment of retinal angiomatous proliferation (RAP) with Bevacizumab (Avastin)

    No full text

    One year follow-up of the bifocal Morcher 43s intraocular lens

    No full text

    Erste Erfahrungen mit der Morcher 43S-Hinterkammerlinse

    Full text link

    Augenverletzungen

    No full text

    Langfristige Entwicklung der Sehfunktion bei Patienten mit Orbitacavernomen

    No full text

    Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease

    No full text
    Proteome profile changes in Alzheimer's disease (AD) brains have been reported. However, it is unclear whether they represent a continuous process, or whether there is a sequential involvement of distinct proteins. To address this question, we used mass spectrometry. We analyzed soluble, dispersible, sodium dodecyl sulfate, and formic acid fractions of neocortex homogenates (mainly Brodmann area 17-19) from 18 pathologically diagnosed preclinical AD, 17 symptomatic AD, and 18 cases without signs of neurodegeneration. By doing so, we identified four groups of AD-related proteins being changed in levels in preclinical and symptomatic AD cases: early-responding, late-responding, gradually-changing, and fraction-shifting proteins. Gene ontology analysis of these proteins and all known AD-risk/causative genes identified vesicle endocytosis and the secretory pathway-related processes as an early-involved AD component. In conclusion, our findings suggest that subtle changes involving the secretory pathway and endocytosis precede severe proteome changes in symptomatic AD as part of the preclinical phase of AD. The respective early-responding proteins may also contribute to synaptic vesicle cycle alterations in symptomatic AD.status: publishe
    corecore